Welcome to Markets Desk, your midday read on what's moving markets and money.
Tesla and SpaceX together shed roughly four hundred fifty billion dollars in market value over just two sessions, in what traders are calling the Musk selloff. The concern is straightforward: a divided Washington threatens the government contracts and regulatory goodwill that underpin the entire Elon Inc. empire, and investors are repricing that risk fast.
Shifting to healthcare, Revolution Medicines is turning heads with its new pancreatic cancer treatment, which posted first-weeks sales so far above expectations that analysts are already calling it one of the best drug launches of all time. That kind of commercial debut signals genuine physician adoption, not just pipeline hype, and the stock is reflecting exactly that.
And on the fiscal side, the Iran conflict is drawing serious attention from economists focused on Social Security's long-term math. War spending puts direct pressure on federal borrowing and entitlement funding timelines, and with retirement security already under structural strain, analysts say the financial consequences for future beneficiaries could be significant and lasting.
That's the tape. Markets Desk, signing off the floor.
